The experimental treatment of 65° hydroalcoholic ethanol (ethanol 65% (v/v)) compounded formulation or water for injection (control) were elaborated at 20 °C and packaged in humidifiers in the hospital pharmacy department, under sterile conditions, as described in our previous work [18 (link)]. Preparations were assigned to the corresponding batch to maintain the blind and sent to the geriatric ward. Allocation of treatments was carried out randomly in a 1:1 ratio according to their order of inclusion on a master randomization list.
Patients in the experimental group received oxygen at 2 L/min moistened with the 65° ethanol compounded formulation contained in the humidifier (INTL CE0482. Ref. 3230, Oximesa Nippon Gases, Madrid, Spain) connected to a Ventimask® (Flexicare Medical Ltd. Mountain Ash, UK), every 8 h (inhalation time 15 min) for 5 days. In the placebo group, water for injection was used instead. In both groups, recommended treatment according to the protocol of COVID-19 clinical management established by the Spanish Ministry of Health at the beginning of the trial was administered concomitantly.
Patients in the experimental group received oxygen at 2 L/min moistened with the 65° ethanol compounded formulation contained in the humidifier (INTL CE0482. Ref. 3230, Oximesa Nippon Gases, Madrid, Spain) connected to a Ventimask® (Flexicare Medical Ltd. Mountain Ash, UK), every 8 h (inhalation time 15 min) for 5 days. In the placebo group, water for injection was used instead. In both groups, recommended treatment according to the protocol of COVID-19 clinical management established by the Spanish Ministry of Health at the beginning of the trial was administered concomitantly.
Free full text: Click here
